Bio-Techne Corporation, a global provider of life science research tools, analytical instruments, and diagnostics, today ...

New SPYRE™ Focus Panels (Stroma and Vessel) broaden modular panel options, enabling deeper targeted insights in spatial biology workflows. SPYRE™ Amplification Kits leverage sequential and enhanced ...

Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...

Bio-Techne is a leading provider of specialized reagents, analytical instruments, and diagnostic solutions for the life sciences and clinical diagnostics sectors. The company leverages a diverse ...

Bio-Techne Corporation (NASDAQ:TECH) is one of the 10 best life sciences stocks to buy according to hedge funds. On February 5, Daniel Arias from Stifel Nicolaus reaffirmed his Hold rating on ...

Cleo Diagnostics (ASX:COV) selects Bio-Techne's Ella ELISA platform to run its ovarian cancer test, advancing toward FDA 510(k) filing and supply deal. Cleo adopts Ella ELISA for ovarian test. Ella ...

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions ...

In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

Nov 5 (Reuters) - Biotech firm Bio-Techne (TECH.O), opens new tab on Wednesday missed Wall Street estimates for first-quarter revenue, hurt by subdued demand for its products, sending its shares down ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...